Synergistic effects of eukaryotic co-expression plasmid-based STAT3-specific siRNA and LKB1 on ovarian cancer in vitro and in vivo.

The signal transducer and activator of transcription 3 (STAT3) are ideal targets for ovarian cancer. Previous studies showed that downregulation of STAT3 using specific short hairpin RNAs (shRNA) can significantly reduce ovarian tumor growth. However, RNA interference does not fully ablate target gene expression due to idiosyncrasies associated with shRNAs and their targets. To enhance the therapeutic efficacy of STAT3-specific shRNA, we employed a combinatorial expression of STAT3-specific shRNA and liver kinase B1 (LKB1), a tumor suppressor. Thus, the LKB1 coding sequences and STAT3-specific shRNAs were constructed in a eukaryotic co-expression plasmid pCDNA3.1, and then transfected into ovarian cancer cells to evaluate the synergistic effects of this combination on anticancer activity and explore the relevant molecular mechanisms. Co-expression of STAT3‑specific siRNA and LKB1 (pSi-STAT3-LKB1) synergistically inhibited ovarian cancer cell growth, invasion and migration, induced cell apoptosis and arrested the cell cycle in vitro when compared with monotherapy. The results showed that the co-expression of plasmid pSi-STAT3-LKB1 inserted subcutaneously into ovarian tumor xenograft resulted in more significant inhibition of tumor growth. Further study showed that the synergistic anti-ovarian cancer effects of the co-expression of STAT3-specific siRNA and LKB1 may be associated with the upregulation of p-p53, p21 and downregulation of survivin, BCL-2 and cyclin D1. Results of the present study suggested that combined therapy with eukaryotic co-expression of the plasmid‑carrying STAT3-specific siRNA and LKB1 is a novel and efficient treatment strategy for human ovarian cancer.

[1]  Ke Huang,et al.  Arctigenin Promotes Apoptosis in Ovarian Cancer Cells via the iNOS/NO/STAT3/Survivin Signalling , 2014, Basic & clinical pharmacology & toxicology.

[2]  Zhong-Xi Ren,et al.  Plasmid-based Stat3-specific siRNA and GRIM-19 inhibit the growth of thyroid cancer cells in vitro and in vivo. , 2014, Oncology reports.

[3]  Ming Zhao,et al.  Downregulation of LKB1 suppresses Stat3 activity to promote the proliferation of esophageal carcinoma cells. , 2014, Molecular medicine reports.

[4]  Chao Zheng,et al.  COX-2 silencing enhances tamoxifen antitumor activity in breast cancer in vivo and in vitro. , 2014, International journal of oncology.

[5]  Wen Zhu,et al.  Synergistic effects of eukaryotic coexpression plasmid carrying LKB1 and FUS1 genes on lung cancer in vitro and in vivo , 2014, Journal of Cancer Research and Clinical Oncology.

[6]  Jing-pu Yang,et al.  Small interfering RNA survivin and GRIM-19 co-expression salmonella plasmid inhibited the growth of laryngeal cancer cells in vitro and in vivo. , 2013, International journal of clinical and experimental pathology.

[7]  D. Kalvakolanu,et al.  Plasmid-based E6-specific siRNA and co-expression of wild-type p53 suppresses the growth of cervical cancer in vitro and in vivo. , 2013, Cancer letters.

[8]  Z. Shao,et al.  LKB1 Inhibits Breast Cancer Partially through Repressing the Hedgehog Signaling Pathway , 2013, PloS one.

[9]  D. Ma,et al.  Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. , 2013, Biochemical and biophysical research communications.

[10]  Yuquan Wei,et al.  Efficient inhibition of intraperitoneal ovarian cancer growth in nude mice by liposomal delivery of short hairpin RNA against STAT3 , 2013, The journal of obstetrics and gynaecology research.

[11]  P. Marignani,et al.  Loss of lkb1 Expression Reduces the Latency of ErbB2-Mediated Mammary Gland Tumorigenesis, Promoting Changes in Metabolic Pathways , 2013, PloS one.

[12]  S. Kaye,et al.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research , 2013, Nature Reviews Cancer.

[13]  C. Telleria.  Repopulation of Ovarian Cancer Cells After Chemotherapy , 2013, Cancer growth and metastasis.

[14]  Wen Zhu,et al.  Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1 , 2012, Cancer Gene Therapy.

[15]  D. Kalvakolanu,et al.  Effects of Plasmid-Based Stat3-Specific Short Hairpin RNA and GRIM-19 on PC-3M Tumor Cell Growth , 2008, Clinical Cancer Research.

[16]  Jongkyeong Chung,et al.  Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC). , 2007, Molecular endocrinology.

[17]  A. Yoshimura,et al.  Loss of SOCS3 Gene Expression Converts STAT3 Function from Anti-apoptotic to Pro-apoptotic* , 2006, Journal of Biological Chemistry.

[18]  D. Bell,et al.  Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant Ovarian Cancer , 2006, Clinical Cancer Research.

[19]  M. Fraser,et al.  Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. , 2006, Gynecologic oncology.

[20]  H. Seno,et al.  STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells , 2004, Oncogene.

[21]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[22]  B. Wiedenmann,et al.  Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. , 2003, Gastroenterology.

[23]  J. Turkson,et al.  Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells , 2003, Oncogene.

[24]  J. Pow-Sang,et al.  Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. , 2002, Cancer research.

[25]  T. Mäkelä,et al.  Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1). , 2002, Human molecular genetics.

[26]  Li Li,et al.  Autocrine-mediated Activation of STAT3 Correlates with Cell Proliferation in Breast Carcinoma Lines* , 2002, The Journal of Biological Chemistry.

[27]  T. Tuschl,et al.  Analysis of gene function in somatic mammalian cells using small interfering RNAs. , 2002, Methods.

[28]  J. Turkson,et al.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.

[29]  Simon C Watkins,et al.  Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Herman,et al.  Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome , 2000, Oncogene.

[31]  T. Mäkelä,et al.  Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Stratton,et al.  A serine/threonine kinase gene defective in Peutz–Jeghers syndrome , 1998, Nature.

[33]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[34]  M. Pesu,et al.  Therapeutic targeting of the Jak/STAT pathway. , 2014, Basic & clinical pharmacology & toxicology.

[35]  J. Blohmer,et al.  Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial. , 2014, Anticancer research.

[36]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[37]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[38]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.